Original Research

Imiquimod Cream 2.5% and 3.75% Applied Once Daily to Treat  External Genital Warts in Men

Cutis. 2015 October;96(4):277-282

References

1. Weinstock H, Berman S, Cates W. Sexually transmitted infections in American youth: incidence and prevalence estimates, 2000. Perspect Sex Reprod Health. 2004;36:6-10.

2. Dunne EF, Unger ER, Sternberg M, et al. Prevalence of HPV infection among females in the United States. JAMA. 2007;297:813-819.

3. Koutsky L. Epidemiology of genital human papillomavirus infection. Am J Med. 1997;102:3-8.

4. Kjaer SK, Tran TN, Sparen P, et al. The burden of genital warts: a study of nearly 70,000 women from the general female population in the 4 Nordic countries. J Infect Dis. 2007;196:1447-1454.

5. Woodhall S, Ramsey T, Cai C, et al. Estimation of the impact of genital warts on health-related quality of life. Sex Transm Infect. 2008;84:161-166.

6. Mortensen GL, Larsen HK. The quality of life of patients with genital warts: a qualitative study. BMC Public Health. 2010;10:113.

7. Wang KL, Jeng CJ, Yang YC, et al. The psychological impact of illness among women experiencing human papillomavirus-related illness or screening interventions.  J Psychsom Obstet Gynaecol. 2010;31:16-23.

8. Lawrence S, Walzman M, Sheppard S, et al. The psychological impact caused by genital warts: has the Department of Health’s choice of vaccination missed the opportunity to prevent such morbidity? Int J STD AIDS. 2009;20:696-700.

9. Winer RL, Kiviat NB, Hughes JP, et al. Development and duration of human papillomavirus lesions, after initial infection. J Infect Dis. 2005;191:731-738.

10. Centers for Disease Control and Prevention. Human papillomavirus: HPV information for clinicians. Atlanta, GA: Centers for Disease Control and Prevention, US  Department of Health and Human Services; April 2007.

11. Forcier M, Musacchio N. An overview of human papillomavirus infection for the dermatologist: disease, diagnosis, management, and prevention. Dermatol Ther. 2010;23:458-476.

12. Scheinfeld N, Lehman DS. An evidence-based review of medical and surgical treatments of genital warts. Dermatol Online J. 2006;12:5.

13. Aldara [package insert]. Bristol, TN: Graceway  Pharmaceuticals, LLC; 2010.

14. Komericki P, Akkilic-Materna M, Strimitzer T, et al. Efficacy and safety of imiquimod versus podophyllotoxin in the treatment of genital warts. Sex Transm Dis. 2011;38:216-218.

15. Beutner KR, Tyring SK, Trofatter KF Jr, et al. Imiquimod, a patient-applied immune-response modifier for treatment of external genital warts. Antimicrob Agents Chemother. 1998;42:789-794.

16. Beutner KR, Spruance SL, Hougham AJ, et al. Treatment of genital warts with an immune-response modifier (imiquimod). J Am Acad Dermatol. 1998;38:230-239.

17. Edwards L, Ferenczy A, Eron L, et al. Self-administered topical 5% imiquimod cream for external anogenital warts. Arch Dermatol. 1998;134:25-30.

18. Fife KH, Ferenczy A, Douglas JM, et al. Treatment of external genital warts in men using 5% imiquimod cream applied three times a week, once daily, twice daily, or three times a day. Sex Transm Dis. 2001;28:226-231.

19. Garland SM, Waddell R, Mindel A, et al. An open-label phase II pilot study investigating the optimal duration of imiquimod 5% cream for the treatment of external genital warts in women. Int J STD AIDS. 2006;17:448-452.

20. Schofer H, Van Ophoven A, Henke U, et al. Randomized, comparative trial on the sustained efficacy of topical imiquimod 5% cream versus conventional ablative methods in external anogenital warts. Eur J Dermatol. 2006;16:642-648.

21. Arican O, Guneri F, Bilgic K, et al. Topical imiquimod  5% cream in external anogenital warts: a randomized, double-blind, placebo-controlled study. J Dermatol. 2004;31:627-631.

22. Gollnick H, Barasso R, Jappe U, et al. Safety and efficacy of imiquimod 5% cream in the treatment of penile genital warts in uncircumcised men when applied three times weekly or once per day. Int J STD AIDS. 2001;12:22-28.

23. Trofatter KF Jr, Ferenczy A, Fife KH. Increased frequency of dosing of imiquimod 5% cream in the treatment of external genital warts in women. Int J Gynecol Obstet. 2002;76:191-193.

24. Baker DA, Ferris DG, Martens MG, et al. Imiquimod 3.75% cream applied daily to treat anogenital warts: combined results from women in two randomized, placebo-controlled studies [published online ahead of print August 24, 2011]. Infect Dis Obstet Gynecol. 2011;2011:806105.

25. Dinh TH, Sternberg M, Dunne EF, et al. Genital warts among 18- to 59-year-olds in the US, National Health and Nutrition Examination Survey, 1999-2004.  Sex Transm Dis. 2008;35:357-360.

26. Insinga RP, Dasbach EJ, Elbasha EH. Assessing the annual economic burden of preventing and treating anogenital human papillomavirus-related disease in the US: analytic framework and review of the literature. Pharmacoeconomics. 2005;23:1107-1122.

27. Koshiol JE, Laurent SA, Pimenta JM. Rate and predictors of new genital warts claims and genital warts-related healthcare utilization among privately insured patients in the United States. Sex Transm Dis. 2004;31:748-752.

28. Insinga RP, Glass AG, Rush BB. The health care costs of cervical human papillomavirus-related disease. Am J Obstet Gynecol. 2004;191:114-120.

The median time to complete clearance  was shorter in the 2 active treatment groups  compared with placebo. For those participants  who attained complete clearance, the median  time to complete clearance ranged from 57 to  59 days in the imiquimod cream 3.75% groups  (studies 1 and 2, respectively), 60 to 74 days in the imiquimod 2.5% cream groups (studies 1 and 2, respectively), and 76 to 81 days with placebo  (studies 2 and 1, respectively).

Safety

Less than one-third of male participants in each treatment group experienced AEs during the studies. The incidence of serious adverse events (SAEs) and AEs leading to study discontinuation was low. In total, 4 participants (0.9% [3 in the imiquimod cream 2.5% group and 1 in the imiquimod cream 3.75% group]) had AEs that led to study discontinuation. Application-site reactions were reported in a total of 46 participants (10.3%). The incidence and severity of local skin reactions was mostly mild or moderate, similar in both active treatment groups, and higher than in the  placebo group. Local skin reactions were coincident with the treatment period and rapidly decreased when treatment was concluded. There were no clinically meaningful trends in vital sign measurements or laboratory measurements.

Comment

Imiquimod cream 5% has been shown to be a safe and effective treatment of EGWs. Our study was designed to evaluate lower concentrations of imiquimod cream (2.5% and 3.75%), which may permit daily dosing and a shortened treatment course in men with EGWs.

Efficacy of imiquimod cream 2.5% and 3.75% was established through both primary and secondary end points, though only the higher concentration was significantly more effective than placebo in both studies. In addition, a number of participants who were not completely cleared following 8 weeks of treatment went on to be completely cleared at EOS, demonstrating continued activity of imiquimod despite cessation of active treatment.

Imiquimod cream 3.75% was particularly effective when compared to placebo, with 18.6% of participants completely cleared at EOS, though the PP (observed case) results (22.7%) may be more encouraging and can be used to motivate patients.

Although there are limitations in making direct comparisons between studies, complete clearance rates in our studies were lower than those reported previously with imiquimod cream 5%.¹⁷ Lower  efficacy rates might be expected given the differences in methodology. In the 2 studies reported here, participants had to have no EGWs (baseline or  new, treated or untreated) in any of the anogenital areas specified to be reported as having  achieved complete clearance. In earlier studies with imiquimod cream 5%, not all anogenital regions  were required to be treated, and any new EGWs  arising during treatment were not included in  the analysis.¹⁷ Also, our analysis focused purely  on a male patient population in which efficacy results tend to be lower regardless of treatment modality employed.

Recurrence is another important issue in the treatment of EGWs. Although not studied specifically in a male population, recurrence rates of  16.7% to 17.7% were seen in the 3 months following  successful treatment with imiquimod cream 2.5% and 3.75% in the 2 pivotal studies. These results were consistent with the recurrence rates reported following successful treatment with imiquimod cream 5%.¹⁷

In general, complete clearance rates increased in a dose-dependent manner. Complete clearance rates were lower in the male subpopulation across all treatment groups compared to those previously reported in females,²⁴ which was consistent with prior results reported for imiquimod cream 5% as well as other topical treatments.¹⁷ It has been suggested that this difference may be due in part to the distribution of female EGWs in areas of less keratinization. Complete clearance rates in the current analysis tended to be higher in male participants with baseline EGWs in anatomic sites with less keratinized skin such as the perianal, perineal, or glans penis areas.

Daily application of imiquimod cream 2.5% and 3.75% generally was well tolerated. Most reported AEs were mild or moderate, and few participants discontinued because of AEs. Few SAEs were reported and none were considered to be treatment related. There was no difference in the incidence rates of AEs between the 2 active treatments. The incidence of SAEs and study discontinuations was much lower than previously reported in the female cohort of these 2 studies.²⁴

Conclusion

In conclusion, 2 well-controlled studies of males with EGWs who were treated for up to 8 weeks with imiquimod cream 2.5% and 3.75% applied daily demonstrated good tolerability and superior efficacy to placebo in complete clearance of all baseline  and newly arising warts in addition to reducing  EGW counts.